Storys zum Thema Medizin, Gesundheit

Schweizerischer Nationalfonds / Fonds national suisse

Speeding up genetic diagnosis of Huntington's disease

Bern (ots) - Elongated segments of DNA cause Huntington's disease and certain other disorders of the brain. Researchers funded by the SNSF have developed a method to determine the length of the mutated genes quickly and easily. People with Huntington's disease suffer from jerky body movements and decreasing mental abilities. The condition usually leads to death 15-20 years after diagnosis. The cause of the disease is a ...

Medasense Biometrics Ltd

Medasense Announces Compatibility with Philips IntelliVue Patient Monitors

Ramat Gan, Israel (ots/PRNewswire) - Medasense Biometrics Ltd., developer of the physiological pain-response monitoring technology (NOL® -- the Nociception Level Index), now supports Philips IntelliVue Patient Monitors for anesthesia and critical care monitoring. (Photo: https://mma.prnewswire.com/media/805789/Medasense_PMD_200_Monitor.jpg ) Commercially available in ...

Debiopharm International SA

Debiopharm Group regains the commercial rights to Trelstar® (Triptorelin pamoate) and looks for new partners in North America

Lausanne, Switzerland (ots) - Debiopharm and Allergan agree to transition the rights to commercialize Trelstar to new licensees. Debiopharm is in advanced discussion with a potential partner in Canada and is engaged in a bidding process for US rights. Debiopharm Group(TM) (Debiopharm - www.debiopharm.com), a ...

Daiichi Sankyo Europe GmbH

Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet

Munich (ots/PRNewswire) - - Daiichi Sankyo Europe will market oral bempedoic acid and bempedoic acid / ezetimibe combination tablet in the European Economic Area and Switzerland - Bempedoic acid is a first-in-class, oral, once-daily ATP Citrate Lyase (ACL) inhibitor that reduces cholesterol and fatty acid synthesis ...

NEMIS TECHNOLOGIES AG

NEMIS Technologies Ltd. Successfully Closes First Seed Financing Round / Swiss Diagnostic Startup Closes Seed Financing Round of CHF 3 Million Within the First Year

Sophia Genetics

SOPHiA GENETICS Raises $77 Million to Accelerate the Democratization of Data-Driven Medicine

San Francisco (ots/PRNewswire) - SOPHiA GENETICS, a leading health tech company, announced today the closing of a $77 million investment round to accelerate the democratization of Data-Driven Medicine. The round was led by Generation Investment Management, a pioneer of sustainable investing, with offices in London and San Francisco. Generation were joined by Idinvest ...

ProBioGen AG

ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals

Berlin (ots/PRNewswire) - Bispecific Antibody for Cancer Treatment Optimized by GlymaxX® Technology ProBioGen AG, a premier service & technology provider for complex therapeutic antibodies and glycoproteins, announced today that the company achieved an undisclosed milestone payment from Merus N.V. (Nasdaq: MRUS) based on Merus' grant of an exclusive license to ...

NORGINE B.V. and KOREA PHARMA CO., LTD.

NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU® in the Republic of Korea

Amsterdam and Seoul, South Korea (ots/PRNewswire) - - Norgine to receive a significant upfront payment and undisclosed sums in sales milestones along with double-digit percentage royalties - Norgine retains full commercial rights to PLENVU® in all unlicensed countries NORGINE B.V. (Norgine), a leading European ...

Merck Healthcare Germany GmbH

Merck and Pfizer Provide Update on JAVELIN Ovarian 100 Trial of Avelumab in Previously Untreated Advanced Ovarian Cancer

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that data from a planned interim analysis of the Phase III JAVELIN Ovarian 100 study of avelumab* did not support the study's initial hypothesis, and therefore the ...

G&G Biotechnology BV

POLYTECH Health & Aesthetics GmbH - Quality Made in Germany Pays Off: CE Approval For Breast Implants From One of the International Leading Companies Currently Confirmed

Dieburg, Germany (ots/PRNewswire) - On December 18, 2018, POLYTECH sold the three millionth implant since its establishment in 1986. The company is the only German manufacturer and present in over 75 countries worldwide. All implants are manufactured in the company's own production facilities in Dieburg near ...

Merck Healthcare Germany GmbH

Merck Announces EMA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

Darmstadt, Germany (ots/PRNewswire) - The information contained is not intended for distribution in the USA, Canada or the UK - European Medicine Agency (EMA) grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer (BTC) - EMA orphan drug designation for M7824 in ...

Merck Healthcare Germany GmbH

Merck Assigns Chimeric Antigen Receptor T-cell (CAR-T) Rights to Intrexon

Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or UK - Agreement enables Merck to maintain an investment in the rapidly advancing oncology field of CAR-T, while focusing its R&D efforts - Intrexon to issue Merck $150 million of Intrexon stock and a $25 million convertible note; Intrexon to receive a $25 million cash investment ...

Merck Healthcare Germany GmbH

Merck Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

Darmstadt, Germany (ots/PRNewswire) - The information contained is not intended for distribution in the USA, Canada or the UK - FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer - First regulatory designation for M7824 following recent presentation of ...

Merck Healthcare Germany GmbH

Merck in Agreement With Cyclica for AI-augmented Screening Platform to Expand Research Capabilities

Darmstadt, Germany (ots/PRNewswire) - Not intended for distribution in the USA, Canada or UK - Agreement to screen discovery and early development compounds using artificial intelligence and computational biophysics - Cloud-based in silico platform that screens small molecules to determine polypharmacological ...

World Heart Federation

World Congress of Cardiology & Cardiovascular Health 2018 Opens in Dubai

Dubai, Uae (ots/PRNewswire) - - Professor David Wood, President of the World Heart Federation, welcomes more than 5000 cardiologists, doctors, nurses, and health and policy experts from around the world to Dubai for WCC 2018 at a time when the opportunities for a sustainable impact on cardiovascular health have never been greater - World Heart Federation Inaugural ...

Hitachi Medical Systems Europe Holding AG

2

Hitachi Medical Systems Europe introduces the third generation of non-invasive intracardiac blood flow visualization technology, at EuroEcho Imaging 2018

Kyowa Kirin International PLC

Kyowa Kirin Announces POTELIGEO® Receives Marketing Authorisation in Europe for the Treatment of Mycosis Fungoides and Sézary Syndrome

Tokyo (ots/PRNewswire) - POTELIGEO will be the first biologic agent targeting CCR4 to be available for patients in Europe. Kyowa Hakko Kirin Co., Ltd., (Kyowa Kirin) announces today that it has received a European Commission decision granting a marketing authorisation to POTELIGEO® (Generic name: mogamulizumab), a ...

Zentiva

Zentiva and PHOENIX Form Strategic Partnership in Europe

Prague (ots/PRNewswire) - Zentiva and PHOENIX joined forces this week for an inaugural Annual Partnership meeting in Prague to kick off a strategic partnership between the two healthcare companies in Europe. (Logo: https://mma.prnewswire.com/media/788903/Zentiva_Logo.jpg ) "At PHOENIX group we believe that Zentiva is an excellent fit for partnering at European level, thanks to their strong heritage, broad portfolio of ...

SAKK - Swiss Group for Clinical Cancer Research

The GIST Group Switzerland, the support group for patients with gastrointestinal stromal tumor, has awarded its science prize for the ninth time.

Merck Healthcare Germany GmbH

Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canada and UK-based media Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of chemotherapy, compared ...

Royal Philips

Philips Debuts Noninvasive Ventilator With High Flow Therapy to Improve Patient Care

Amsterdam (ots/PRNewswire) - - Philips V60 Plus ventilator receives CE Mark, expands on Philips' commitment and leadership in hospital respiratory care - New comprehensive solution enhances clinician workflow and maximizes equipment efficiency to help drive earlier intervention in respiratory distress Royal Philips (https://www.philips.com/) (NYSE: PHG) (AEX: PHIA), a ...

Inceptua

Head of Global Patient Access Joins Inceptua

Luxembourg (ots/PRNewswire) - Inceptua Group today announces that Clive Whitcher joins Inceptua as Vice President, Head of Global Patient Access. (Logo: https://mma.prnewswire.com/media/739136/Inceptua_Group_Logo.jpg ) "Clive joining the team to focus on patient access strengthens our commercialization capabilities, offering even greater support to our partner companies as they try to reach patients in need," says Alan ...

Nyxoah S.A

Nyxoah Raises EUR15 Million in New Financing, Completes BLAST OSA Clinical Study

Mont-Saint-Guibert, Belgium (ots/PRNewswire) - Nyxoah S.A., a medical device company focused on the development and commercialization of a best-in-class hypoglossal nerve stimulation (HGNS) therapy for the treatment of Obstructive Sleep Apnea (OSA), announced today that it successfully raised an additional EUR15 million ($17.1 million USD) in their most recent round of ...

Primary Care Diabetes Europe (PCDE)

Primary Care Diabetes Europe Issues Call to Action Against Clinical Inertia in the Treatment of Type-2 Diabetes

Ekeren, Belgium (ots/PRNewswire) - Research identifies lack of primary care physician adherence to treatment guidelines among the challenges to optimal care for patients with type-2 diabetes Primary Care Diabetes Europe (PCDE) today issued a call to action (https://www.pcdeurope.org/early-action/) challenging ...

Schweizerischer Nationalfonds / Fonds national suisse

Latsis Prize 2018: Andrea Ablasser unlocks the secret of rapid virus defence

Schweizerischer Nationalfonds / Fonds national suisse

Innovations in ultrasound imaging improve breast cancer detection

Bern (ots) - A new ultrasound technique can help distinguish benign breast tumours from malignant ones. The technology was developed with support from the Swiss National Science Foundation. Ultrasound is one of the three main technologies used in medical imaging. It is more compact and affordable than nuclear magnetic resonance imaging (MRI) techniques, and safer than x-rays. But the images it produces are often difficult ...

COMPASS Pathways

COMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment-resistant Depression

London (ots/PRNewswire) - COMPASS Pathways (https://compasspathways.com/), a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health, has received Breakthrough Therapy designation from the US Food and Drug Administration (FDA) for its psilocybin therapy for ...

Janssen Pharmaceutica

New Phase 2 Data Show Stelara® (ustekinumab) Sustained Improvement in Disease Activity in Adults With Systemic Lupus Erythematosus Through One Year

Beerse, Belgium (ots/PRNewswire) - - Janssen presents one-year data from continued Phase 2 lupus study during plenary session at 2018 American College of Rheumatology (ACR) / Association for Rheumatology Health Professionals (ARHP) Annual Meeting The Janssen Pharmaceutical Companies of Johnson & Johnson today ...

UCB Pharma

UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis Into Confirmatory Development Phase

Brussels (ots/PRNewswire) - - Positive outcomes in proof-of-concept study with subcutaneous rozanolixizumab in patients with myasthenia gravis (MG): clinically meaningful improvement in multiple disease-related endpoints - Strong 68% mean reduction of Serum IgG and IgG Autoantibodies observed - Safety profile ...

Hovione

Hovione Increases Production Capacity

Loures, Portugal (ots/PRNewswire) - 'One Site Shop' expands to respond to growing demands Hovione announces plan to increase production capacity in oral dosage forms in Portugal, to strengthen the integrated offering. New commercial scale equipment for blending, tableting and coating will complement existing development small scale equipment. This decision to expand follows growing customer demand since, one year ago ...